Compare GSK plc (GSK) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.22 (market cap $560.32M). The key difference: GSK plc is far larger — about 164× Direxion Daily FTSE China Bull 3x Shares's market cap, and GSK plc pays a 3.9% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| GSK | YINN | |
|---|---|---|
Market Cap | $91.88B | $560.32M |
Volume | 7,730,529 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $52.69 |
52-Week Low | $43.24 | $21.45 |
Typical Hold Time | 93 Days | 25 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
YINN trades at $25.17, up 6.83% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks fundamental financial data disclosure, with key valuation and profitability ratios unavailable. Recent news highlights China's economic policies and export controls, which may influence the fund's underlying holdings.
The outlook is cautious due to bearish technicals and opaque fundamentals. Risks include exposure to Chinese market volatility and regulatory changes. Analyst sentiment is not clearly defined without current consensus data, requiring careful monitoring of emerging financial disclosures and geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
